Ask The Rheumatologist LastManStand85
2 years 4 months ago
#IgG4 Pearls
Thanks for sharing
Isolated ⬆️ serum #IgG4 level
✅ How high? 5x ULN ➡️ PPV 75%
✅Typical organ(s) involved?
❓Another explanation
Dr Jone Stone
#Rheumatology #EULAR2024 https://t.co/UVKmH57iVM https://t.co/uxHBl0I3cM
Jilaine Bolek Berquist BolekBerqui
2 years 4 months ago
EULAR guidelines for screening for TB in rheumatic disease patients
#EULAR2024 https://t.co/jaixl8lGkY
Prof. Denis Poddubnyy DrPoddubnyy
2 years 4 months ago
Setting a standard for imaging reporting in patients with suspected axial spondyloarthritis is an important part of our efforts toward improving the early and accurate diagnosis of SpA:
https://t.co/zYbcL1CaTP https://t.co/1jnBDBSDNv
Artem Minalyan, MD, DABOM AMinalyan
2 years 4 months ago
NEW biomarkers in #MAS
1️⃣ IL-18 (available at some 🏥)⭐️
2️⃣ S100A12
3️⃣ CXCL9/10
🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder!
🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷
#macrophage
#EULAR2024
#genetics
#rheumx https://t.co/Uot3JjrWs8
Tuhina Neogi, MD, PhD Tuhina_Neogi
2 years 4 months ago
DMOADs in #osteoarthritis at #EULAR2024: 1) Tonia Vincent: StepUp OA endotype SF proteomics —> endothelial to mesenchymal transition proteins. 2) Phil Conaghan: proregenerative (& degeneration slowing) therapies in pipeline. 3) @Larhumato: novel RCT designs & structure outcomes
TheDaoIndex KDAO2011
2 years 4 months ago
POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0
Nouf Al hemmadi NoufAhmedAlham2
2 years 4 months ago
Recommendation for management of fatigue in people with rheumatic disease.
Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it.
I will also add yearly blood work including:
1- VitD
2-HBA1c and LDl
3-TsH. https://t.co/3QvPqMxZSN
Rheumatology & Rheumatology Advances in Practice RheumJnl
2 years 4 months ago
Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @drceowen, @drdavidliew et al. characterise PMR using whole-body PET/CT 👀
➡️ https://t.co/tbu0DgAFIS https://t.co/W06YbYyjRx
Tuhina Neogi, MD, PhD Tuhina_Neogi
2 years 4 months ago
Mapping the knee #osteoarthritis joint-nerve interactome — presented by @AM_Malf at #EULAR2024. Anatomical and molecular neuroplasticity occurs during OA onset + progression in the joint and DRG. Cool imaging of nerves and their activity with lightsheet microscopy in mice https://t.co/cre6LEVhle
Nouf Al hemmadi NoufAhmedAlham2
2 years 4 months ago
Maintenance of remission in GPA/MPA.
RTX for 48 months sounds good to me.
#EULAR2024 https://t.co/5YGwOHhCuX
Annals of the Rheumatic Diseases ARD_BMJ
2 years 4 months ago
Potential efficacy of JAK inhibitors in VEXAS syndrome
#EULAR2024
NZ https://t.co/HziLUgo1gA
EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite abstracts and presentations from today, day 3 in Vienna.
Aurelie Najm AurelieRheumo
2 years 4 months ago
500+ pts AxSPA
No difference in drug discontinuation between IL-17i, TNFi, IL23i over time
Adjusted for CRP, co-medication w/ MTX + classic covariates
IL-17i and IL-23i had experienced a higher number bDMARD failures
#EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca
